ORIC ORIC Pharmaceuticals, Inc.

NASDAQ
$7.70

ORIC Pharmaceuticals, Inc. (ORIC) is expected to report earnings on February 15, 2027, after the market close. The consensus earnings estimate is a loss of $0.45 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.1% since its last earnings release on November 16, 2026.

ORIC Pharmaceuticals, Inc. Missed Consensus Estimates
Monday, November 16, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · 4:05 PM ET
Earnings Whisper
-
vs ($0.45)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.86

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.